Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2
a randomised, double-blind, placebo-controlled, phase 1 trial
Chappell, Keith J
Mordant, Francesca L
Li, Zheyi
Wijesundara, Danushka K
Ellenberg, Paula
Lackenby, Julia A
Cheung, Stacey T M
Modhiran, Naphak
Avumegah, Michael S
Henderson, Christina L
Hoger, Kym
Griffin, Paul
Bennet, Jillian
Hensen, Luca
Zhang, Wuji
Nguyen, Thi H O
Marrero-Hernandez, Sara
Selva, Kevin J
Chung, Amy W
Tran, Mai H
Tapley, Peter
Barnes, James
Reading, Patrick C
Nicholson, Suellen
Corby, Stavroula
Holgate, Thomas
Wines, Bruce D
Hogarth, P Mark
Kedzierska, Katherine
Purcell, Damian F J
Ranasinghe, Charani
Subbarao, Kanta
Watterson, Daniel
Young, Paul R
Munro, Trent P
text
monographic
eng
Keith J Chappell [and twenty four others]
Lancet Infect Dis . 2021 Apr 19;S1473-3099 (21) 00200-0.
doi: 10.1016/S1473-3099(21)00200-0.
COVID-19 Vaccines
immunology
Placebo Effects
Adjuvants, Immunologic
210505
20210505162300.0